Swoop Launches Predictive AI Adherence Targeting

Swoop , the leading provider of custom direct-to-consumer (DTC) and healthcare provider (HCP) audiences for the pharmaceutical and life sciences industry, today announced the launch of Predictive AI Adherence Targeting.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, September 12, 2023
Information
Tags: 
Other Science, Pharmaceutical, Research, Software, Artificial Intelligence, Data Management, Science, Technology, Digital Marketing, Other Communications, Biotechnology, Diabetes, Public Relations, Investor Relations, Marketing, Advertising, Health, Communications, Health Technology, Sclerosis, DTC, Network, ML, Intelligence, SDOH, NAI, RWD, HCP, Patient, Machine learning, Artificial intelligence, Diagnosis, AI, Medical device, Pharmaceutical industry, Swoop
Geotags: 
UNITED STATES, NORTH AMERICA, NEW YORK
Summary
Key Points: 
  • Swoop , the leading provider of custom direct-to-consumer (DTC) and healthcare provider (HCP) audiences for the pharmaceutical and life sciences industry, today announced the launch of Predictive AI Adherence Targeting.
  • Examples of the precision healthcare marketers can leverage with Swoop’s Predictive AI Adherence Targeting include:
    94% of all patients who became non-adherent in the next 30 days were accurately predicted for a type 2 diabetes drug.
  • “This represents just the beginning of what predictive modeling can bring to healthcare marketing, allowing brands to better understand their audience, accurately target them and optimize engagement before a real world event has even occurred.”
    Swoop Predictive AI Adherence Targeting can be applied to any condition – common or rare, sensitive or non-sensitive.
  • Contact [email protected] for more information and a custom analysis of how your brand can benefit from Predictive AI Adherence Targeting.


Swoop, the leading provider of custom direct-to-consumer (DTC) and healthcare provider (HCP) audiences for the pharmaceutical and life sciences industry, today announced the launch of Predictive AI Adherence Targeting. Having pioneered the use of machine learning (ML) and artificial intelligence (AI) in conjunction with real world data (RWD) to build privacy-safe, brand exclusive segments of ideal patient and provider populations, this first-of-its-kind targeting methodology allows healthcare advertisers to predict and precisely engage the patients who are most likely to become non-adherent within the next 30 days, as well as their associated HCPs.

“Until now, real world data targeting has focused on what has historically occurred in the healthcare ecosystem, such as a diagnosis or a prescription, rather than predict what is likely to happen in the future,” said Scott Rines, President of Swoop. “Through advanced ML and AI, this breakthrough targeting allows brands to proactively intercept patients and their HCPs at one of the most critical moments in the treatment journey: just prior to a patient becoming non-adherent.”

As many as 50% of patients with long-term chronic conditions fail to appropriately take their medications, making non-adherence a $500-billion-per-year challenge for the healthcare industry. By applying privacy-safe ML/AI to a RWD universe of more than 300 million de-identified patient journeys with a 10-year lookback and 65 billion anonymized social determinants of health (SDOH) signals, Swoop predicts the likelihood of every patient on a therapy becoming non-adherent in the next 30 days. Brands can leverage this intelligence for timely and impactful activation targeting those most likely to become non-adherent. Examples of the precision healthcare marketers can leverage with Swoop’s Predictive AI Adherence Targeting include:

  • 94% of all patients who became non-adherent in the next 30 days were accurately predicted for a type 2 diabetes drug.
  • 92% of all patients who became non-adherent in the next 30 days were accurately predicted for a multiple sclerosis treatment.
  • 91% of all patients who became non-adherent in the next 30 days were accurately predicted for a depression therapy.

“The end result is that patients are more likely to stay on life-improving treatments, benefiting their health and the healthcare system, while pharmaceutical and life sciences manufacturers realize improved commercial outcomes,” added Rines. “This represents just the beginning of what predictive modeling can bring to healthcare marketing, allowing brands to better understand their audience, accurately target them and optimize engagement before a real world event has even occurred.”

Swoop Predictive AI Adherence Targeting can be applied to any condition – common or rare, sensitive or non-sensitive. Swoop is HIPAA-certified, a member of the Network Advertising Initiative (NAI) and all its technology is built on a patented privacy-by-design data infrastructure.

Contact [email protected] for more information and a custom analysis of how your brand can benefit from Predictive AI Adherence Targeting.

ABOUT SWOOP

Swoop (www.swoop.com), part of Real Chemistry, empowers the world’s leading pharmaceutical brands to better-educate patients about disease states and the therapies that could remedy their conditions, as well as enable them to become active participants in their treatment journey. Swoop’s HIPAA-certified and NAI-accredited system of engagement has uncovered over 6,000 unique target audiences for precisely activating patient populations and their healthcare ecosystems through omnichannel marketing strategies. By utilizing artificial intelligence, machine learning and evolutionary computation in conjunction with a real world data universe of over 300 million de-identified patients and 65 billion anonymized social determinants of health signals, Swoop’s segments are superior in audience quality, lead to optimal conversion and drive increased Rx lift. It’s no wonder that 18 of the top 20 healthcare marketing agencies and 42 of the top 50 pharmaceutical companies power their marketing efforts with Swoop.

Copyright: 
Copyright Business Wire 2023